Regenxbio: RGX-121 FDA Review Extended Amidst Robust Clinical Data and Investor Confidence

ソース：

[1] Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome (https://seekingalpha.com/article/4820197-rege ...)[2] Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome (NASDAQ:RGNX) | Seeking Alpha (https://vertexaisearch.cloud.google.com/groun ...)[3] Agios Pharmaceuticals and the FDA Delay for Pyrukynd in Thalassemia: Assessing the Materiality of Safety Concerns and REMS Submission on Commercial Potential and Stock Valuation - AInvest (https://vertexaisearch.cloud.google.com/groun ...)